Advanced search
Publication Cover
Acta Cardiologica Volume 79, 2024 - Issue 3
Submit an article Journal homepage
50
Views
0
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Conduction system disease management in patients candidate and/or treated for the aortic valve disease: an Italian Survey promoted by Italian Association of Arrhythmology and Cardiac Pacing (AIAC)

Matteo Ziacchia Division of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3617-2739View further author information
ORCID Icon,
Alberto Spadottoa Division of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyView further author information
,
Pietro Palmisanob Cardiology Unit, Azienda Ospedaliera “Card G. Panico”, Tricase, ItalyView further author information
,
Federico Guerrac Cardiology Unit, Università Politecnica delle Marche, Ancona, ItalyView further author information
,
Roberto De Pontid Division of Cardiology, Università degli studi dell’Insubria, Varese, ItalyView further author information
,
Gabriele Zanottoe Cardiology Unit, Ospedale di Legnago ULSS, Veneto, ItalyView further author information
,
Matteo Bertinif Division of Cardiology, Arcispedale S.Anna, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, ItalyView further author information
,
Mauro Biffia Division of Cardiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyView further author information
&
Giuseppe Borianig Cardiology Unit, University of Modena and Reggio Emilia, Modena, ItalyView further author information
 show all
Pages 367-373 | Received 04 Jul 2022, Accepted 01 Jan 2024, Published online: 05 Mar 2024

References

  • Coffey S, Cairns BJ, Iung B. The modern epidemiology of heart valve disease. Heart. 2016;102(1):75–85. doi: 10.1136/heartjnl-2014-307020.
  • Yadgir S, Johnson CO, Aboyans V, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990–2017. Circulation. 2020;141(21):1670–1680. doi: 10.1161/CIRCULATIONAHA.119.043391.
  • Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019;140(14):1156–1169. doi: 10.1161/CIRCULATIONAHA.119.041080.
  • Eveborn GW, Schirmer H, Heggelund G, et al. The evolving epidemiology of valvular aortic stenosis. The Tromsø study. Heart. 2013;99:396–400.
  • Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. doi: 10.1093/eurheartj/ehab395.
  • Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation. 2011;124(18):1964–1972. doi: 10.1161/CIRCULATIONAHA.111.040022.
  • Baron SJ, Arnold SV, Wang K, et al. Health status benefits of transcatheter vs surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk: results From the PARTNER 2 randomized clinical trial. JAMA Cardiol. 2017;2(8):837–845. doi: 10.1001/jamacardio.2017.2039.
  • Baron SJ, Magnuson EA, Lu M, et al. Health status after transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2019;74(23):2833–2842. doi: 10.1016/j.jacc.2019.09.007.
  • Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705. doi: 10.1056/NEJMoa1814052.
  • Socie P, Nicot F, Baudinaud P, et al. Frequency of recovery from complete atrioventricular block after cardiac surgery. Am J Cardiol. 2017;120(10):1841–1846. doi: 10.1016/j.amjcard.2017.07.090.
  • Robich MP, Schiltz NK, Johnston DR, et al. Risk factors and outcomes of patients requiring a permanent pacemaker after aortic valve replacement in the United States. J Card Surg. 2016;31(8):476–485. doi: 10.1111/jocs.12769.
  • Baldi E, Compagnone M, Errigo D, et al. Long-term percentage of ventricular pacing in patients requiring pacemaker implantation after transcatheter aortic valve replacement: a multicenter 10-year experience. Heart Rhythm. 2020;17(11):1897–1903. doi: 10.1016/j.hrthm.2020.05.040.
  • Saia F, Gandolfo C, Palmerini T, et al. In-hospital and thirty-day outcomes of the SAPIEN 3 ultra balloon-expandable transcatheter aortic valve: the S3U registry. EuroIntervention. 2020;15(14):1240–1247. doi: 10.4244/EIJ-D-19-00541.
  • Rheude T, Pellegrini C, Lutz J, et al. Transcatheter aortic valve replacement with balloon-expandable valves. JACC Cardiovasc Interv. 2020;13(22):2631–2638. doi: 10.1016/j.jcin.2020.07.013.
  • Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715. doi: 10.1056/NEJMoa1816885.
  • Strutture Cardiochirurgiche; 2022 [cited 2022 Apr 10]. Available from: https://www.sicch.it/societa/strutture-cardiochirurgiche
  • Tarantini G, Esposito G, Musumeci G, et al. Updated SICI-GISE position paper on institutional and operator requirements for transcatheter aortic valve implantation. G Ital Cardiol. 2018;19:519–529.
  • Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427–3520. doi: 10.1093/eurheartj/ehab364.
  • Siontis GCM, Jüni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR. J Am Coll Cardiol. 2014;64(2):129–140. doi: 10.1016/j.jacc.2014.04.033.
  • Gama F, de Araújo Gonçalves P, Abecasis J, et al. Predictors of pacemaker implantation after TAVI in a registry including self, balloon and mechanical expandable valves. Int J Cardiovasc Imaging. 2022;38(1):225–235. doi: 10.1007/s10554-021-02365-2.
  • Ravaux JM, Mauro MD, Vernooy K, et al. Impact of bundle branch block on permanent pacemaker implantation after transcatheter aortic valve implantation: a meta-analysis. J Clin Med. 2021;10(12):2719. doi: 10.3390/jcm10122719.
  • Jørgensen TH, De Backer O, Gerds TA, et al. Mortality and heart failure hospitalization in patients with conduction abnormalities after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(1):52–61. doi: 10.1016/j.jcin.2018.10.053.
  • Auffret V, Puri R, Urena M, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation. 2017;136(11):1049–1069. doi: 10.1161/CIRCULATIONAHA.117.028352.
  • Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;65(5):437–448. doi: 10.1016/j.jacc.2014.11.027.
  • Rodés-Cabau J, Urena M, Nombela-Franco L, et al. Arrhythmic burden as determined by ambulatory continuous cardiac monitoring in patients with new-onset persistent left bundle branch block following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(15):1495–1505. doi: 10.1016/j.jcin.2018.04.016.
  • Chung MK. Cardiac surgery: postoperative arrhythmias. Crit Care Med. 2000;28(10 Suppl.):N136–N144. doi: 10.1097/00003246-200010001-00005.
  • Leyva F, Qiu T, McNulty D, et al. Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm. 2017;14(4):529–534. doi: 10.1016/j.hrthm.2016.11.029.
  • Gaede L, Kim W-K, Liebetrau C, et al. Pacemaker implantation after TAVI: predictors of AV block persistence. Clin Res Cardiol. 2018;107(1):60–69. doi: 10.1007/s00392-017-1158-2.
  • Muntané-Carol G, Okoh AK, Chen C, et al. Ambulatory electrocardiographic monitoring following minimalist transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(24):2711–2722. doi: 10.1016/j.jcin.2021.08.039.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.